Login to Your Account

Savara so good: Aerovanc inhaled vancomycin nears pivotal with $20M series C

By Randy Osborne
Staff Writer

Tuesday, March 1, 2016

Savara Pharmaceuticals Inc. CEO Rob Neville told BioWorld Today that $20 million in series C money will "get us at least to the first patient and beyond, but not all the way through" the pivotal phase III trial with lead candidate Aerovanc (vancomycin). 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription